Undertreatment of osteoporosis in residents of nursing homes: Population-based study with use of the systematic assessment of geriatric drug use via epidemiology (SAGE) database

Endocrine Practice

Volumn 8, Issue 5, 2002, Pages 335-342

  Rojas Fernandez, Carlos H ^a   Lapane, Kate L ^a   MacKnight, Chris ^a   Howard, Kellee A ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

AGED; ARTICLE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG USE; FALLING; FEMALE; FRACTURE; GERIATRIC CARE; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HOSPITAL ADMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; NURSING HOME; OSTEOPOROSIS; PHYSICAL DISABILITY; POPULATION RESEARCH; PREDICTION; PROGNOSIS; RESIDENTIAL CARE; RISK ASSESSMENT; STATISTICAL MODEL; TERMINAL DISEASE;

EID: 0036739156     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.8.5.335     Document Type: Article

References (46)

1. Rungby J, Hermann A, Mosekilde L. Epidemiology of osteoporosis: implications for drug therapy. Drugs Aging. 1995;6:470-478.
2. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997; 12:24-35.
3. Magaziner J, Simonsick EM, Kashner TM, Hebei JR, Kenzora JE. Survival experience of aged hip fracture patients. Am J Public Health. 1989;79:274-278.
4. Katelaris AG, Cumming RG. Health status before and mortality after hip fracture. Am J Public Health. 1996;86: 557-560.
5. Marottoli RA, Berkman LF, Cooney LM Jr. Decline in physical function following hip fracture. J Am Geriatr Soc. 1992;40:861-866.
6. Lyles KW. Management of patients with vertebral compression fractures. Pharmacotherapy. 1999; 19(1 Pt 2):21S-24S.
7. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736-746.
8. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
9. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637-1642.
10. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992; 117:1-9.
11. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women: study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995;122:9-16.
12. Ettinger B, Black DM, Mitlak BH, et al (Multiple Outcomes of Raloxifene Evaluation [MORE] Investigators). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial [erratum in JAMA. 1999;282:2124]. JAMA. 1999;282:637-645.
13. Black DM, Cummings SR, Karpf DB, et al (Fracture Intervention Trial Research Group). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
14. Harris ST, Watts NB, Genant HK, et al (Vertebral Efficacy With Risedronate Therapy [VERT] Study Group). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: randomized controlled trial. JAMA. 1999; 282:1344-1352.
15. Chesnut CH III, Silverman S, Andriano K, et al (PROOF Study Group). A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med. 2000;109:267-276.
16. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992;305:556-561.
17. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density: the Rancho Bernardo Study. JAMA. 1997;277:543-547.
18. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. 2000. Available at: http://www.nof.org/in/shtml.dll/physguide/index.htm.
19. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
20. Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int. 1999;9:151-157.
21. Bernabei R, Gambassi G, Lapane K, et al (SAGE [Systematic Assessment of Geriatric Drug Use via Epidemiology] Study Group). Characteristics of the SAGE database: a new resource for research on outcomes in long-term care. J Gerontol A Biol Sci Med Sci. 1999;54: M25-M33.
22. Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54:M546-M553.
23. Morris JN, Fries BE, Mehr DR, et al. MDS cognitive performance scale. J Gerontol. 1994;49:M174-M182.
24. Morris JN, Hawes C, Fries BE, et al. Designing the national resident assessment instrument for nursing homes. Gerontologist. 1990;30:293-307.
25. Hartmaier SL, Sloane PD, Guess HA, Koch GG, Mitchell CM, Phillips CD. Validation of the Minimum Data Set Cognitive Performance Scale: agreement with the Mini-Mental State Examination. J Gerontol A Biol Sci Med Sci. 1995;50:M128-M133.
26. Gambassi G, Landi F, Peng L, et al (SAGE [Systematic Assessment of Geriatric Drug Use via Epidemiology] Study Group). Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoepidemiology. Med Care. 1998;36: 167-179.
27. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 1990;163(5 Pt 1):1438-1444.
28. Handa VL, Landerman R, Hanlon JT, Harris T, Cohen HJ. Do older women use estrogen replacement? Data from the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE). J Am Geriatr Soc. 1996;44:1-6.
29. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130:545-553.
30. Martin A, Chandler JM, Girman CJ, Magaziner J, Sloane P, Zimmerman SI. Awareness of osteoporosis in the nursing home [abstract]. Gerontologist. 1998;38(special issue I):175.
31. Goldis ME. Assessing the prevalence and treatment of osteoporosis in the nursing home population [abstract]. J Am Geriatr Soc. 1998;46:S111.
32. Chiang L, Ouslander J, Schnelle J, Reuben DB. Dually incontinent nursing home residents: clinical characteristics and treatment differences. J Am Geriatr Soc. 2000;48:673-676.
33. Gurwitz JH, Monette J, Rochon P, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157:978-984.
34. Aronow WS. Prevalence of use of beta blockers and of calcium channel blockers in older residents with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc. 1996;44:1075-1077.
35. Aronow WS. Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc. 1998;46:615-616.
36. Heston LL, Garrard J, Makris L, et al. Inadequate treatment of depressed nursing home elderly. J Am Geriatr Soc. 1992;40:1117-1122.
37. Won A, Lapane K, Gambassi G, Bernabei R, Mor V, Lipsitz LA (SAGE [Systematic Assessment of Geriatric Drug Use via Epidemiology] Study Group). Correlates and management of nonmalignant pain in the nursing home. J Am Geriatr Soc. 1999;47:936-942.
38. Gambassi G, Lapane K, Sgadari A, et al (SAGE [Systematic Assessment of Geriatric Drug Use via Epidemiology] Study Group). Prevalence, clinical correlates, and treatment of hypertension in elderly nursing home residents. Arch Intern Med. 1998;158:2377-2385.
39. Bernabei R, Gambassi G, Lapane K, et al (SAGE [Systematic Assessment of Geriatric Drug Use via Epidemiology] Study Group). Management of pain in elderly patients with cancer [erratum in JAMA. 1999;281:136]. JAMA. 1998;279:1877-1882.
40. Gloth FM III, Tobin JD. Vitamin D deficiency in older people. J Am Geriatr Soc. 1995;43:822-828.
41. Liu BA, Gordon M, Labranche JM, Murray TM, Vieth R, Shear NH. Seasonal prevalence of vitamin D deficiency in institutionalized older adults. J Am Geriatr Soc. 1997;45:598-603.
42. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone mineral density in elderly women. N Engl J Med. 1993;329:1141-1146.
43. Grady D, Rubin SM, Pettiti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117:1016-1037.
44. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989;321:1306-1311.
45. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
46. Smith NL, Psaty BM, Furberg CD, et al. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med. 1999;159:1574-1578.